San Francisco, CA, United States of America

Michelle Akerman



Average Co-Inventor Count = 14.9

ph-index = 3

Forward Citations = 34(Granted Patents)


Company Filing History:


Years Active: 2009-2010

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Michelle Akerman: Innovator in Pharmaceutical Compositions

Introduction

Michelle Akerman is a prominent inventor based in San Francisco, CA (US). She has made significant contributions to the field of pharmaceutical compositions, particularly in the treatment of metabolic disorders. With a total of 3 patents to her name, her work is paving the way for advancements in medical treatments.

Latest Patents

Among her latest patents, one notable invention focuses on compounds, pharmaceutical compositions, and methods for use in treating metabolic disorders. This invention provides compounds that are useful for modulating insulin levels in a subject, characterized by the general formula Q-L-P-L-M-X-L-A. The definitions of the variables Q, L, P, L, M, X, L, and A are detailed within the patent. This invention also outlines compositions and methods for utilizing these compounds, particularly for the treatment of type II diabetes.

Career Highlights

Michelle Akerman is currently employed at Amgen Inc., a leading biotechnology company. Her work at Amgen has allowed her to explore innovative solutions in the pharmaceutical industry. Her dedication to research and development has positioned her as a key player in her field.

Collaborations

Throughout her career, Michelle has collaborated with notable colleagues, including Jonathan B. Houze and Jiwen Liu. These collaborations have further enhanced her research and contributed to the success of her inventions.

Conclusion

Michelle Akerman's contributions to pharmaceutical innovations are noteworthy and impactful. Her work continues to influence the treatment of metabolic disorders, showcasing her commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…